// App-Quantinova.ai

2194 : A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

Researchers

Presenter

  • John Mascarenhas

Principal Investigators

  • Claire Harrison

  • Jean-Jacques Kiladjian

  • Ruben Mesa

  • Rami S. Komrokji

  • Steffen Koschmieder

  • Alessandro Vannucchi

  • Tymara Berry

  • Laurie Sherman

  • Souria Dougherty

  • Libo Sun

  • Fei Huang

  • Ying Wan

  • Faye Feller

  • Aleksandra Rizo

  • Srdan Verstovsek

Medical Centers

  • Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Hospital Saint Antoine, Paris, France

  • University of Texas Health Science Center San Antonio, San Antonio, TX

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • RWTH Aachen University, Aachen, Germany

  • CRIMM, AOU Careggi, University of Florence, Florence, Italy

  • Geron Corporation, Parsippany, NJ

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

  • United Kingdom

  • France

  • Germany

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myeloid neoplasms

  • Essential thrombocythemia

  • Polycythemia vera

  • Myelofibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxyurea

  • Hydroxycarbamide

  • Thalidomide

  • Imetelstat

  • Interferon

  • Danazol

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Open Label

  • Multinational

  • Multicenteric

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved